Compare compounds
Pick up to 3 compounds to see protocols, mechanisms, study endpoints and safety findings side by side.
Peptijournal · BPC-157 vs TB-500 · https://peptijournal.com/compare?c=bpc-157,tb-500 · Printed
01Protocol
BPC-157
- Start
- 0.25 mg
- Range
- 0.25–0.5 mg
- Frequency
- Once or twice daily
- Cycle
- 4–8 weeks
- Vials
- 5 / 10 mg
TB-500
- Start
- 2 mg
- Range
- 2–5 mg per week
- Frequency
- 2× weekly (loading), then weekly
- Cycle
- 4–6 week loading, then maintenance
- Vials
- 5 / 10 mg
- Titration
- Weeks 1–4: 2–2.5 mg, twice weekly
- Weeks 5+: 2 mg, once weekly
02Quick calculator
BPC-157
TB-500
03Mechanism of action
BPC-157
BPC-157 is a 15-amino-acid fragment of a protein found in gastric juice. Preclinical studies associate it with increased growth-hormone-receptor expression, angiogenesis pathways (including VEGF-related signalling) and lower inflammatory cytokines. The exact receptor target is not established.
TB-500
TB-500 is a synthetic peptide based on the active region of thymosin β4, a 43-amino-acid protein that binds G-actin and is involved in cell migration. Thymosin β4 research links it to endothelial and keratinocyte migration, angiogenesis and wound repair.
04Study endpoints
BPC-157
- A 2025 systematic review found 36 studies: 35 preclinical and 1 clinical.
- Animal models showed improved functional, structural and biomechanical outcomes in muscle, tendon, ligament and bone injuries.
- The only clinical study was a small retrospective series: 7 of 12 patients with chronic knee pain reported relief for more than 6 months.
TB-500
- In a rat full-thickness wound model, thymosin β4 increased re-epithelialisation by 42% at day 4 and up to 61% at day 7 vs saline.
- Treated wounds contracted at least 11% more by day 7, with more collagen deposition and new blood vessels.
- Keratinocyte migration rose 2–3-fold in cell-culture assays.
05Safety & regulatory findings
BPC-157
- Not FDA-approved for any use and listed as prohibited by the World Anti-Doping Agency.
- Reported half-life is under 30 minutes; it is metabolised in the liver and cleared by the kidneys.
- Preclinical safety studies reported no organ toxicity, but the 2025 review found no clinical safety data.
TB-500
- Most evidence is on full-length thymosin β4; data on the TB-500 fragment itself is limited.
- Not approved for human use; listed as prohibited by the World Anti-Doping Agency.